Innate Pharma Sa Class A · EURONEXT:IPH
Innate Pharma Sa Class A — Q3 2025 Earnings Presentation
21 slides from Innate Pharma Sa Class A's earnings presentation, Nov 13, 2025
Slide 1: Q3 2025 Business Update and Financial Results
Q3 2025 Business Update and Financial Results November 13 2025
Slide 2: Disclaimer
Disclaimer This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document contains certain forward-looking statements, including those wi
Slide 3: Conference call agenda
Q3 2025 Business Update and Financial Results Conference call agenda Strategic Overview and Outlook Jonathan Dickinson Chief Executive Officer Clinical Pipeline Progress Sonia Quaratino Chief Medical Officer Lacutamab Commercial Opportunity Stéphanie Cornen VP, IR, Communication & Commercial Strateg
Slide 4: Strategic Overview and Outlook
Strategic Overview and Outlook Jonathan Dickinson, CEO 4
Slide 5: Positive momentum around lacutamab
Positive momentum around lacutamab FDA clearance to proceed with TELLOMAK-3, a Confirmatory Phase 3 trial of lacutamab in CTCL Progressing toward Phase 3 initiation in H1 2026 Potential accelerated approval in Sezary syndrome supported by Phase 2 data once Phase 3 is underway Lacutamab KOL Event Wel
Slide 6: Leveraging our scientific know-how to advance life-enhancing cancer therapy candidates
Leveraging our scientific know-how to advance life-enhancing cancer therapy candidates Expertise in antibody- Clinical pipeline High value assets with engineering to drive focused on high unmet near-term commercial innovation medical need potential Strong fundamentals in antibody Advancing a portfol
Slide 7: Delivering on our strategic priorities and driving value through focused execution
Delivering on our strategic priorities and driving value through focused execution Clinical programs Research Organization Focus investment Advance our next Streamline the on highest-value ADCs toward organization clinical assets development IPH4502 Multiple programs Fit-for-purpose Lacutamab organi
Slide 8: Clinical pipeline progress
Clinical pipeline progress Sonia Quaratino, CMO 8
Slide 9: A First-in-Human Phase 1 clinical trial evaluating IPH4502 in solid tumors
IPH4502 A First-in-Human Phase 1 clinical trial evaluating IPH4502 in solid tumors A Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502 as a Single Agent in Advanced Solid Tumors (NCT06781983) STUDY POPULATION Dose escalation Dose optimization OBJECTIVES n=
Slide 10: PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III NSCLC
monalizumab PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer ✓ Three Phase 2 Trials supporting rationale of combination in early NSCLC (COAST, NeoCOAST, NeoCOAST-2) Phase 3 PACIFIC-9 data expected in H2 2026 Barlesi et al. Futur
Slide 11: Lacutamab: from niche market entry to broader opportunity
lacutamab Lacutamab: from niche market entry to broader opportunity Phase 3 in preparation Phase 3 in preparation Phase 2 ongoing BLA filing planned based on Phase 2 data once Phase 3 is underway 03 02 PTCL 01 Aggressive lymphoma with poor CTCL Mycosis Fungoides (MF) prognosis and high unmet need CT
Slide 12: Lacutamab shows clinical benefit in Sézary syndrome, an aggressive subtype of CTCL
lacutamab Lacutamab shows clinical benefit in Sézary syndrome, an aggressive subtype of CTCL with limited treatment option Global ORR = 42.9% (31.4-55.1) Long term follow up data from the TELLOMAK Phase 2 trial Data cut-off (DCO): OCT 17, 2024 63 patients with ≥2 prior lines of systemic therapy, pos
Slide 13: In mycosis fungoides, lacutamab shows robust clinical activity regardless of KIR3DL2 expression level
lacutamab In mycosis fungoides, lacutamab shows robust clinical activity regardless of KIR3DL2 expression level Global ORR = 19.6% (13.2, 28.1) KIR3DL2 ≥ 1% (N=48) KIR3DL2 <1% (N=59) Long term follow up data from the ORR 20.8%(11.7 - 34.3) ORR 18.6% (10.7 – 30.4) TELLOMAK Phase 2 trial Data cut-off
Slide 14: FDA clearance to proceed with TELLOMAK-3, a confirmatory phase 3 trial of lacutamab in CTCL
lacutamab FDA clearance to proceed with TELLOMAK-3, a confirmatory phase 3 trial of lacutamab in CTCL Open-label, multi-center, randomized comparative Phase 3 study of lacutamab in R/R patients with MF or SS Primary Key Secondary Endpoint Endpoints Lacutamab KEY ELIGIBILITY SS Cohort Randomization P
Slide 15: Commercial opportunity
Commercial opportunity Stéphanie Cornen, VP IR, communication & commercial strategy 15
Slide 16: Focused opportunity in specialized centers treating SS and MF
lacutamab Focused opportunity in specialized centers treating SS and MF Sezary Syndrome (SS) Mycosis Fungoides (MF) Near-term Phase 3 objective is to establish lacutamab De-risked opportunity in the US as the new 2L standard of care • Higher incidence from real-world data1 than public • Higher incid
Slide 17: Lacutamab market potential in CTCL
lacutamab Lacutamab market potential in CTCL Patient Incidence Up to $150m* Up to $500m** >$500m** # Expand use of CTCL systemic therapy for Market 1L Systemic therapy early-stage and expansion other CTCL patients Mycosis Mycosis 2L fungoides fungoides Sezary Sezary Sezary 3L+ syndrome syndrome synd
Slide 18: Closing Remarks
Closing Remarks Jonathan Dickinson, CEO 18
Slide 19: Driving growth through our lead clinical programs
Driving growth through our lead clinical programs IPH4502 LACUTAMAB MONALIZUMAB Nectin-4 ADC in solid tumors Anti-KIR3DL2 mAb in CTCL Anti-NKG2A mAb in NSCLC Phase 1 ongoing Phase 3 in preparation Phase 3 ongoing • Pharmacologically active dose • FDA clearance to proceed with • PACIFIC-9 Phase 3 in
Slide 20: Strong short-term catalysts across Innate's portfolio
Strong short-term catalysts across Innate’s portfolio 2026 H1 2026 H2 ≥ 2027 IPH4502 Lacutamab AA in SS Phase 1 Data Monalizumab Monalizumab BLA Phase 3 AZ PACIFIC-9 Lacutamab IPH4502 Ph1/2 Data readouts Ph3 TELLOMAK-3 Initiation Expansion cohorts data Cash position of €56.4m* as of September 30, 20
Slide 21: Thank you
EURONEXT : IPH.PA NASDAQ : IPHA Thank you www.innate-pharma.com investors@innate-pharma.fr 21